These are all highly specific antibodies for multiple sclerosis (MS), myelinating oligodendrocyte glycoprotein antibody-associated disease (MOGAD) [4], and neuromyelitis optica (NMOSD), respectively [5]. This evidence concerns the gene MOG and myeloid sarcoma.